A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs IMM-201 (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 10 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 ClinicalTrials.gov record.
- 10 Aug 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.